Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Phasebio Pharmaceuticals Inc (PHAS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 314,064
  • Shares Outstanding, K 24,498
  • Annual Sales, $ 670 K
  • Annual Income, $ -23,850 K
  • 60-Month Beta N/A
  • Price/Sales 517.10
  • Price/Cash Flow N/A
  • Price/Book 6.78
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -10.71
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/26/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.44
  • Number of Estimates 1
  • High Estimate -0.44
  • Low Estimate -0.44
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.47 +134.37%
on 03/19/19
16.65 -23.00%
on 04/09/19
+6.59 (+105.78%)
since 03/18/19
3-Month
2.56 +400.78%
on 03/12/19
16.65 -23.00%
on 04/09/19
+9.04 (+239.15%)
since 01/18/19

Most Recent Stories

More News
PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced the closing...

PHAS : 12.82 (-9.08%)
PhaseBio Announces Pricing of Public Offering of Common Stock

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced the pricing...

PHAS : 12.82 (-9.08%)
Latest Biotechnology Advancements may be Key to Unlock new Autism Treatments

According to the Centers for Disease Control, autism affects an estimated 1 in 59 children in the United States today. The Autism Speaks website defines the main problem for researchers/practitioners...

QBIO : 1.8300 (-1.08%)
GERN : 1.77 (+1.72%)
INSM : 29.84 (+1.29%)
PHAS : 12.82 (-9.08%)
CMRX : 2.62 (+0.38%)
PhaseBio Announces Proposed Public Offering of Common Stock

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that it...

PHAS : 12.82 (-9.08%)
PhaseBio Stock Up on Breakthrough Therapy Status for PB2452

FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

AZN : 38.80 (+0.08%)
ANIP : 68.88 (-0.17%)
KMDA : 6.17 (-1.44%)
PHAS : 12.82 (-9.08%)
PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced it has...

PHAS : 12.82 (-9.08%)
PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that the...

PHAS : 12.82 (-9.08%)
PhaseBio Stock Up on Positive Data From PB2452 Phase I Study

PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.

CELG : 93.76 (-0.57%)
AZN : 38.80 (+0.08%)
KMDA : 6.17 (-1.44%)
PHAS : 12.82 (-9.08%)
Thinking about buying stock in Altimmune Inc., Dare Bioscience Inc., Phasebio Pharmaceuticals Inc., Stoneco Ltd., or Tilray Inc.?

InvestorsObserver issues critical PriceWatch Alerts for ALT, DARE, PHAS, STNE, and TLRY.

ALT : 2.74 (-2.84%)
STNE : 26.51 (-23.69%)
DARE : 1.01 (-5.61%)
PHAS : 12.82 (-9.08%)
Clinical Trials for Leukemia Exhibiting Encouraging Advancements

Recent developments mentioned in industry sourced article from Medicalexpress.com, a research and technology news service, it was encouraging to see an optimistic headline in cancer treatments. One article...

AMRN : 18.06 (+2.27%)
MRK : 73.19 (-0.99%)
MBRX : 1.11 (+14.08%)
DARE : 1.01 (-5.61%)
PHAS : 12.82 (-9.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade PHAS with:

Business Summary

PhaseBio Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. The company's product consists of PB2452, a novel reversal agent for the antiplatelet...

See More

Key Turning Points

2nd Resistance Point 14.58
1st Resistance Point 13.70
Last Price 12.82
1st Support Level 12.31
2nd Support Level 11.80

See More

52-Week High 16.65
Last Price 12.82
Fibonacci 61.8% 11.26
Fibonacci 50% 9.60
Fibonacci 38.2% 7.94
52-Week Low 2.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar